STPG2

Across TCGA pan-cancer cohorts, STPG2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STPG2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher STPG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STPG2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

READ, ESCA, and LUAD are the cancer types where STPG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	All	0.198	0.829	.001	23	view →
ESCA	OS	Median	II,III,IV	0.301	0.707	.005	12	view →
LUAD	DFS	Median	All	0.360	0.668	.025	3	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	3	view →
SKCM	OS	Median	All	1.000	0.868	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STPG2–READ (OS)

Open the READ breakdown →